Entasis Therapeutics Holdings (Entasis Therapeutics Holdings) Quality Rank

View and export this data going back to 2018. Start your Free Trial

What is Entasis Therapeutics Holdings Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:

Interest coverage
Zscore
Debt to revenue
Equity to asset
Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:

Operating margin mean rank (10-year mean average profit margine)
Operating margin growth rank
Fscore
Predictability rank
Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
Num of year profit (number of years that is profitable within the last 10 years)
ROIC median (10-year median of ROIC)

Entasis Therapeutics Holdings Quality Rank Related Terms

Thank you for viewing the detailed overview of Entasis Therapeutics Holdings's Quality Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Entasis Therapeutics Holdings (Entasis Therapeutics Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entasis Therapeutics Holdings Inc (NAS:ETTX) » Definitions » Quality Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

35 Gatehouse Drive, Waltham, MA, USA, 02451

Website

https://www.entasistx.com

Entasis Therapeutics Holdings Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. The company's pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting Gram-negative infections including Pseudomonas).

Executives

Theravance Inc	10 percent owner	1350 OLD BAYSHORE HIGHWAY, SUITE 400, BURLINGAME CA 94010
Kristie Ann Wagner	officer: VP, Principal Fin & Acct Off	35 GATEHOUSE DRIVE WALTHAM MA 02451
David Altarac	officer: Chief Medical Officer	35 GATEHOUSE DRIVE WALTHAM MA 02451
Michael Gutch	officer: Chief Fin. and Bus. Officer	C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109
John Patrick Mueller	officer: Chief Development Officer	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Manoussos Perros	director, officer: President and CEO	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Ruben Tommasi	officer: Chief Scientific Officer	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Matthew Ronsheim	officer: See Remarks	35 GATEHOUSE DRIVE WALTHAM MA 02451
Elizabeth M Keiley	officer: General Counsel	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Anna Diaz Triola	officer: Chief Commercial Officer	35 GATEHOUSE DRIVE WALTHAM MA 02451
Innoviva Strategic Opportunities Llc	director, 10 percent owner	1209 ORANGE STREET, WILMINGTON DE 19801
Eric Wilson Kimble	officer: Chief Commercial Officer	C/O ENTASIS THERAPEUTICS HOLDINGS INC. 35 GATEHOUSE DRIVE WALTHAM MA 02451
Frazier Life Sciences Viii, L.p.	10 percent owner	601 UNION STREET, SUITE 3200, SEATTLE WA 98101
Howard Mayer	director	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Heather Behanna	director	C/O ENTASIS THERAPEUTICS HOLDINGS INC., 35 GATEHOUSE DRIVE, WALTHAM MA 02451